We use essential cookies to make this site work.
We also use analytics cookies, by accepting you agree to their use.
You have accepted analytics cookies. You can change this choice at any time in settings.
You have rejected analytics cookies. You can change this choice at any time in settings.
STAY INFORMED! - If you are interested in receiving newsletters and updates, please send us your email to cksdrg@health.gov.sk
A List of requests and responses via feedback - CKS DRG
Thank You for your feedback. Your requests are being processed systematically according to the received date.
Current number of requests: 1050
Number of requests till 31.03.2026: 1006
Number of requests after 31.03.2026: 44
Handled suggestions: 690
Open suggestions: 37
Pending suggestions: 274
Suggestions downloaded by the submitter: 49
Neurologická klinika
Created at: 27.03.2025
Processed at: 07.04.2026
Attributable item
Incentive to create
Requirement for PP medicine - tenecteplase
The opinion is set out in feedback number 659 - https://www.cksdrg.sk/sk/spatna-vazba/stanoviska/659
Neurologické oddelenie FNsP Žilina
Liptovská nemocnica
Created at: 26.03.2025
Merck Sharp & Dohme, s.r.o.
Processed at: 02.04.2026
Please include Keytruda (pembrolizumab) in the indication ca endometrium in case of a final decision of the Ministry of Health of the Slovak Republic in the DRG as an attributable item.
NA-Keytruda (pembrolizumab) in the indication KN868 ca endometrial
patients with endometrial cancer requiring first-line treatment for primary advanced or recurrent cancer during hospitalisation according to the above IO
The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.
Please include Keytruda (pembrolizumab) in the indication NSCLC in case of a valid decision of the Ministry of Health of the Slovak Republic as of 1.1.2026 in the DRG as a creditable item.
NA-Keytruda (pembrolizumab) is pending ID34154 in the indication in question
nSCLC patients requiring first-line treatment for metastatic squamous NSCLC with PD-L1 TPS 1-49% during hospitalization according to the above IO
